1. Ambiance Ventures USA Focus on Brazil & Latin America

4. Ambiance Ventures USA

5. Ambiance Ventures USA FOCUS: Opportunities for GENERICS IN BRAZIL, Latin America: An Overview

9. Ambiance Ventures USA Local Situation: There are approx. 100 producers with registrations for generic medicines in Brazil. Medley and EMS are the leaders (65% combined market share). Eurofarma and Aché (15% combined market share) Problem with sub-bioequivalent products of smaller manufacturers

11. Ambiance Ventures USA THE OPPORTUNITY IN BRAZIL & LATIN AMERICA: … ..Right Time, Right Market! (with the Right approach!) Nearly $140 billion of branded products coming off patent by 2016 President of Brazil: The Hon. Luiz Inácio Lula da Silva

12. Ambiance Ventures USA Blockbusters in Brazil: A number of products are due to lose their patent protection between 2007 and 2012, bringing market opportunities worth US$307.2 million to the generics sector in Brazil Key Products: Plavix® in 2007 (US$ 41 million) Mercilon® in 2009 (US$58 million) Viagra® in 2011(US$73 million) Lipitor® in 2011 (US$54 million) In March 2007, ANVISA authorized the registration of generic alternatives to oral contraceptives and endogenous hormones: Valued at US$481 million in 2006 and generic producers are expected to account for 60% by 2012

13. Ambiance Ventures USA HIV Generics: Market Potential in Brazil Brazil had an estimated HIV population of 620,000 adults and children , with 14,000 individuals dying from AIDS each year. President Lula da Silva has issued a 'compulsory license' that bypasses the patent on the HIV drug Sustiva® (Efavirenz), marketed by Merck & Co. as Stocrin® in developing countries Brazil's will therefore bypass Merck's patent Sustiva® (efavirenz) in order to manufacture it as a lower-priced generic. This will increase therapy-access for many HIV/AIDS patients. The Brazilian Govt. is seeking lower prices to limit the cost of its program providing free treatment to all people in Brazil infected with HIV. Brazil can issue ‘Compulsory Licences’ and allow local generic production of imported Antiretrovirals. Thus far, it has negotiated drug price reductions and encouraged local production under license. ……a great business opportunity for local manufacturers. Brazil will save $30 million this year by purchasing generic Efavirenz and will cut $237 million from its HIV/AIDS drug bill through 2012 ireuld expire

18. Ambiance Ventures USA

20. Ambiance Ventures USA

23. Ambiance Ventures USA OUR SPECIALTY: Leverage low cost contract manufacture at our facilities! NEUTRAL LABEL, PRIVATE LABEL CONTRACT MANUFACTURE: Generics, Cosmetics, Diagnostics Custom Packaging – For Re-distribution Neutral (‘generic drug’) labeling per Ministerio da Saude requirements In Portuguese / English / Spanish (for re-export) Private labeling with your own Brand Name, Company Identity, Compliant with regulations – Pharmacies, HMOs, Export, Secondary Distribution

28. Ambiance Ventures USA Contact: Jay Nadkarni Ambiance Ventures, USA Swiftwater, Pennsylvania 18370 (USA) Tel: 570/ 460-1804; Fax: 570/ 688-0975 [email_address] Contact: Valerian Lobo LOB International, India G-6 Khira Industrial Estates, B.M. Bhargava Rd. Santa Cruz (W), Mumbai 400 054 (INDIA) Tel: 9122- 2661-5006, 9122-2661-6008 [email_address]